重组人粒细胞集落刺激因子治疗非小细胞肺癌化学治疗后骨髓抑制的疗效观察

Observation on the Clinical Efficacy of Recombinant Human Granulocyte Colony-Stimulating Factor in Treating Bone Marrow Suppression after Chemotherapy in Non-Small Cell Lung Cancer Patients

目的：探讨重组人粒细胞集落刺激因子治疗非小细胞肺癌化学治疗（化疗）后骨髓抑制的临床疗效。方法：回顾性分析我院2011～2013年70例非小细胞癌化疗后骨髓抑制患者的资料，将患者随机分为观察组和对照组，各35例，观察组患者应用重组人粒细胞集落刺激因子（rhG-CSF，造血生长因子）治疗，对照组患者采用地榆升白片治疗，比较两组患者中性粒细胞和白细胞数目恢复情况及恢复时间，同时观察不同rhG-CSF剂量对患者治疗效果的影响。结果：观察组患者骨髓抑制恢复时间短、有效率高，与对照组患者比较差异明显，有统计学意义（P〈0.05）。骨髓抑制时间与rhG-CSF用药剂量呈负相关。结论：重组人粒细胞集落刺激因子对治疗非小细胞肺癌化疗所致的骨髓抑制效果好，同时要根据患者骨髓抑制情况，调整用药剂量和用药时间。

To evaluate the clinical efifcacy of recombinant human granulocyte colony-stimulating factor treating bone marrow suppression after chemotherapy in non-small cell lung patients.Methods：A retrospective analysis was performed on 70 cases of non-small cell lung cancer patients demonstrated bone marrow suppression after chemotherapy in our hospital in 2011~2013.All the patients were randomly divided into the observation group and the control group, and each group contained 35 cases respectively. Patients in the observation group were treated with recombinant human granulocyte colony-stimulating factor （rhG-CSF） while patients in the control group were treated with Diyushengbai tablet. The recovery level and time of neutrophils and total leukocyte between the two groups were compared, and the different doses of rhG-CSF affecting on the results of treatment were analyzed. Results：The recovery time of bone marrow suppression in the observation group was shorter and the efifcacy rate was higher compared to the control group. The differences was statistically signiifcant （P〈0.05）.The duration of bone marrow suppression was negatively correlated with rhG-CSF dose.Conclusion：The recombinant human granulocyte colony-stimulating factor is a promising treatment for chemotherapy-induced myelosuppression in non-small cell lung cancer. The drug dose and administration time should be adjust according to the level of bone marrow suppression.